文献速递前列腺癌

HORRAD 随机对照试验:ADT 联合前列腺放疗与单纯 ADT 对初诊骨转移前列腺癌生存的影响

Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial.
PubMed 文献 · Eur Urol · 2018-09-25

HORRAD 是一项多中心随机对照试验,纳入 432 例 PSA>20ng/ml 且骨扫描提示原发性骨转移的前列腺癌患者,比较 ADT 联合前列腺外照射放疗与单纯 ADT。结果显示两组中位总生存无显著差异(45 个月 vs 43 个月,HR 0.90,95%CI 0.70-1.14,p=0.4),但置信区间不能排除实质性生存获益,仍需进一步研究确认。

要点

  • ADT 联合前列腺 EBRT 未显著延长骨转移前列腺癌患者的总生存。
  • 放疗组中位至 PSA 进展时间 15 个月,对照组 12 个月,粗 HR 0.78(p=0.02)。
  • 该试验置信区间不能排除实质性生存获益,结论需进一步研究确认。

核心结论

  • 在初诊骨转移前列腺癌患者中,ADT 联合前列腺 EBRT 与单纯 ADT 相比,总生存无显著差异,但置信区间不能排除实质性生存获益。

研究设计与样本

  • HORRAD 为多中心随机对照试验,2004 至 2014 年间纳入 432 例 PSA>20ng/ml 且骨扫描示原发性骨转移的前列腺癌患者。
  • 患者随机分为 ADT 联合 EBRT 组(放疗组)与单纯 ADT 组(对照组),主要终点为总生存,次要终点为至 PSA 进展时间。

主要发现

  • 中位随访 47 个月,放疗组中位总生存 45 个月(95%CI 40.4-49.6),对照组 43 个月(95%CI 32.6-53.4),p=0.4。
  • 总生存 HR 为 0.90(95%CI 0.70-1.14,p=0.4),无显著差异。
  • 放疗组中位至 PSA 进展时间 15 个月(95%CI 11.8-18.2),对照组 12 个月(95%CI 10.6-13.4),粗 HR 0.78(95%CI 0.63-0.97,p=0.02)。

关键数值与推荐

  • 入组标准为 PSA>20ng/ml 且骨扫描示原发性骨转移,中位 PSA 水平 142ng/ml。
  • 67% 的患者骨转移灶超过 5 个。

临床怎么用

  • 对于初诊骨转移前列腺癌患者,不应仅凭本试验结果常规推荐在 ADT 基础上加用前列腺 EBRT 以改善总生存。
  • 放疗对至 PSA 进展时间的影响及总生存置信区间提示的潜在获益,需结合后续研究及患者个体情况评估。

局限性

  • 总生存置信区间较宽,不能排除实质性生存获益。
  • 作者指出需进一步研究确认本试验结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The cornerstone of standard treatment for patients with primary bone metastatic prostate cancer (mPCa) is androgen deprivation therapy (ADT). Retrospective studies suggest a survival benefit for treatment of the primary prostatic tumour in mPCa, but to date, no randomised-controlled-trials (RCTs) have been published addressing this issue. OBJECTIVE: To determine whether overall survival is prolonged by adding local treatment of the primary prostatic tumour with external beam radiation therapy (EBRT) to ADT. DESIGN, SETTING, AND PARTICIPANTS: The HORRAD trial is a multicentre RCT recruiting 432 patients with prostate-specific antigen (PSA) >20ng/ml and primary bone mPCa on bone scan between 2004 and 2014. INTERVENTION: Patients were randomised to either ADT with EBRT (radiotherapy group) or ADT alone (control group). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Primary endpoint was overall survival. Secondary endpoint was time to PSA progression. Crude and adjusted analyses were applied to evaluate treatment effect. RESULTS AND LIMITATIONS: Median PSA level was 142ng/ml and 67% of patients had more than five osseous metastases. Median follow up was 47 mo. Median overall survival was 45 mo (95% confidence interval [CI], 40.4-49.6) in the radiotherapy group and 43 mo (95% CI: 32.6-53.4) in the control group (p=0.4). No significant difference was found in overall survival (hazard ratio [HR]: 0.90; 95% CI: 0.70-1.14; p=0.4). Median time to PSA progression in the radiotherapy group was 15 mo (95% CI: 11.8-18.2), compared with 12 mo (95% CI: 10.6-13.4) in the control group. The crude HR (0.78; 95% CI: 0.63-0.97) was statistically significant (p=0.02). CONCLUSIONS: The current RCT comparing ADT to ADT with EBRT to the prostate in patients with primary bone mPCa did not show a significant difference in overall survival, although the CI cannot exclude a substantial survival benefit. Further research is needed to confirm our findings. PATIENT SUMMARY: This study investigated the effect of adding radiation therapy to the prostate to hormonal therapy in prostate cancer patients with metastasis to the bone at diagnosis. In our patient group, additional radiotherapy did not improve overall survival. Further research is needed to confirm our findings. TWITTER SUMMARY: Adding radiotherapy to the prostate in patients with bone metastatic prostate cancer does not improve overall survival.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Boevé LMS, Hulshof MCCM, Vis AN, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol. 2018. PMID: 30266309. doi:10.1016/j.eururo.2018.09.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。